2016-08330. Donor Screening Recommendations To Reduce the Risk of Transmission of Zika Virus by Human Cells, Tissues, and Cellular and Tissue-Based Products; Guidance for Industry; Availability; Correction
-
Start Preamble
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Notice of availability; correction.
SUMMARY:
The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of Monday, March 7, 2016 (81 FR 11808). The document announced a guidance for industry entitled “Donor Screening Recommendations to Reduce the Risk of Transmission of Zika Virus by Human Cells, Tissues, and Cellular and Tissue-Based Products.” The document was published with an incorrect docket number in the ADDRESSES section. This document corrects that error.
Start Further InfoFOR FURTHER INFORMATION CONTACT:
Lisa Granger, Office of Policy, Planning, Legislation, and Analysis, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 3330, Silver Spring, MD 20993-0002, 301-796-9115.
End Further Info End Preamble Start Supplemental InformationSUPPLEMENTARY INFORMATION:
In FR Doc. 2016-04893, appearing on page 11808 in the Federal Register of Monday, March 7, 2016, the following correction is made:
1. On page 11808, in the third column, the docket number is corrected to read “FDA-2016-D-0768”.
Start SignatureDated: April 6, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016-08330 Filed 4-11-16; 8:45 am]
BILLING CODE 4164-01-P
Document Information
- Published:
- 04/12/2016
- Department:
- Food and Drug Administration
- Entry Type:
- Notice
- Action:
- Notice of availability; correction.
- Document Number:
- 2016-08330
- Pages:
- 21577-21577 (1 pages)
- Docket Numbers:
- Docket No. FDA-2016-D-0768
- PDF File:
- 2016-08330.pdf
- Supporting Documents:
- » Attachment 1 Guidance for Industry Recommendations for Donor Screening, Deferral, and Product Management to Reduce the Risk of Transfusion Transmission of Zika Virus re: Comment from Cerus
- » Reference 27 - Notes from the Field_ Evidence of Zika Virus Infection in Brain and Placenta re Donor Screening Recommendations to Reduce the Risk of Transmission of Zika Virus by Human Cells, Tissues, and Cellular and Tissue-Based Products; Guidance for I
- » Reference 26 - Zika virus intrauterine infection causes fetal brain abnormality re Donor Screening Recommendations to Reduce the Risk of Transmission of Zika Virus by Human Cells, Tissues, and Cellular and Tissue-Based Products; Guidance for Industry
- » Reference 25 - Evidence of perinatal transmission of Zika virus re Donor Screening Recommendations to Reduce the Risk of Transmission of Zika Virus by Human Cells, Tissues, and Cellular and Tissue-Based Products; Guidance for Industry
- » Reference 24 - Transmission of Zika Virus Through Sexual Contact with Travelers to Areas of Ongoing Transmission Continental United States 2016 re Donor Screening Recommendations to Reduce the Risk of Transmission of Zika Virus by Human Cells, Tissues, a
- » Reference 23 - Interim Guidelines for Prevention of Sexual Transmission of Zika Virus re Donor Screening Recommendations to Reduce the Risk of Transmission of Zika Virus by Human Cells, Tissues, and Cellular and Tissue-Based Products; Guidance for Indust
- » Reference 22 - Probable Non-vector-borne transmission of Zika virus re Donor Screening Recommendations to Reduce the Risk of Transmission of Zika Virus by Human Cells, Tissues, and Cellular and Tissue-Based Products; Guidance for Industry
- » Reference 21 - Detection of Zika Virus in Semen re Donor Screening Recommendations to Reduce the Risk of Transmission of Zika Virus by Human Cells, Tissues, and Cellular and Tissue-Based Products; Guidance for Industry
- » Reference 20 - Potential sexual transmission of Zika virus re Donor Screening Recommendations to Reduce the Risk of Transmission of Zika Virus by Human Cells, Tissues, and Cellular and Tissue-Based Products; Guidance for Industry
- » Reference 19 - Neurological syndrome, congenital malformations, and Zika virus infections re Donor Screening Recommendations to Reduce the Risk of Transmission of Zika Virus by Human Cells, Tissues, and Cellular and Tissue-Based Products; Guidance for Ind